



## INFORMATION DISCLOSURE STATEMENT

Applicant : Goddard et al.  
App. No : 10/063,718  
Filed : May 8, 2002  
For : SECRETED AND  
TRANSMEMBRANE POLYPEPTIDES  
AND NUCLEIC ACIDS ENCODING  
THE SAME  
Examiner : Sandra L. Wegert  
Art Unit : 1647

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

Enclosed for filing in the above-identified application is a PTO/SB/08 Equivalent listing 6 references to be considered by the Examiner. Also enclosed are 6 foreign patent references and/or non-patent literature as listed on the Information Disclosure Statement.

This Information Disclosure Statement is being filed before the mailing date of a final action and before the mailing of a Notice of Allowance. This Statement is accompanied by the fees set forth in 37 C.F.R. § 1.17(p). The Commissioner is hereby authorized to charge any additional fees which may be required or to credit any overpayment to Account No. 11-1410.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: Oct 6, 2005

By: Daniel Hart

Daniel Hart  
Registration No. 40,637  
Attorney of Record  
Customer No. 30,313  
(619) 235-8550

10/12/2005 ZJUHR1 00000015 10063718

01 FC:1806

180.00 OP

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Application No.	10/063,718
Filing Date	May 8, 2002
First Named Inventor	Goddard et al.
Art Unit	1647
Examiner	Sandra L. Wegert
Attorney Docket No.	GNE.3230R1C149

(Multiple sheets used when necessary)

SHEET 1 OF 1

## FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.	Foreign Patent Document Country Code-Number-Kind Code Example: JP 1234567 A1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T <sup>1</sup>
	1	WO 97/38085	10-16-1997	California Pacific Medical Center		

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>1</sup>
	2	ALBERTS, et al. 1994. <i>Molecular Biology of the Cell</i> , 3rd Edition, pp. 1216-1217. New York: Garland Publishing.	
	3	ANDERSON, et al. 1997. A comparison of selected mRNA and protein abundances in human liver. <i>Electrophoresis</i> , 18:533-537.	
	4	FESSLER, et al. 2002. A genomic and proteomic analysis of activation of the human neutrophil by lipopolysaccharide and its mediation by p38 mitogen-activated protein kinase. <i>The Journal of Biological Chemistry</i> , 277(35):31291-31302.	
	5	STRAUSBERG, et al., 2003, Accession No. AAH20905.1.	
	6	TOKUNAGA, et al. 2000. Application of quantitative RT-PCR using "TaqMan" technology to evaluate the expression of CK 18 mRNA in various cell lines. <i>J. Exp. Clin. Cancer Res.</i> , 19(3):375-381.	

1941000\092005

Examiner Signature	Date Considered
--------------------	-----------------

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

T<sup>1</sup> - Place a check mark in this area when an English language Translation is attached.